Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5179012
Max Phase: Preclinical
Molecular Formula: C48H69N7O11
Molecular Weight: 920.12
Associated Items:
ID: ALA5179012
Max Phase: Preclinical
Molecular Formula: C48H69N7O11
Molecular Weight: 920.12
Associated Items:
Canonical SMILES: COC(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)[C@H](CN(Cc1ccc(-c2ccccn2)cc1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)OC(=O)OC(OC(=O)[C@H](N)C(C)C)C(C)C)C(C)(C)C
Standard InChI: InChI=1S/C48H69N7O11/c1-29(2)37(49)42(58)65-43(30(3)4)66-46(61)64-36(35(26-31-18-14-13-15-19-31)51-40(56)38(47(5,6)7)52-44(59)62-11)28-55(54-41(57)39(48(8,9)10)53-45(60)63-12)27-32-21-23-33(24-22-32)34-20-16-17-25-50-34/h13-25,29-30,35-39,43H,26-28,49H2,1-12H3,(H,51,56)(H,52,59)(H,53,60)(H,54,57)/t35-,36-,37+,38+,39+,43?/m0/s1
Standard InChI Key: DLUXWMAGQWCCLR-VBIXTJAZSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 920.12 | Molecular Weight (Monoisotopic): 919.5055 | AlogP: 5.88 | #Rotatable Bonds: 20 |
Polar Surface Area: 238.84 | Molecular Species: NEUTRAL | HBA: 14 | HBD: 5 |
#RO5 Violations: 3 | HBA (Lipinski): 18 | HBD (Lipinski): 6 | #RO5 Violations (Lipinski): 4 |
CX Acidic pKa: 11.77 | CX Basic pKa: 7.48 | CX LogP: 7.34 | CX LogD: 7.00 |
Aromatic Rings: 3 | Heavy Atoms: 66 | QED Weighted: 0.04 | Np Likeness Score: -0.08 |
1. A M Subbaiah M, Subramani L, Ramar T, Desai S, Sinha S, Mandlekar S, Kadow JF, Jenkins S, Krystal M, Subramanian M, Sridhar S, Padmanabhan S, Bhutani P, Arla R, Meanwell NA.. (2022) Improving Drug Delivery While Tailoring Prodrug Activation to Modulate Cmax and Cmin by Optimization of (Carbonyl)oxyalkyl Linker-Based Prodrugs of Atazanavir., 65 (16.0): [PMID:35952307] [10.1021/acs.jmedchem.2c00632] |
2. A M Subbaiah M, Subramani L, Ramar T, Desai S, Sinha S, Mandlekar S, Kadow JF, Jenkins S, Krystal M, Subramanian M, Sridhar S, Padmanabhan S, Bhutani P, Arla R, Meanwell NA.. (2022) Improving Drug Delivery While Tailoring Prodrug Activation to Modulate Cmax and Cmin by Optimization of (Carbonyl)oxyalkyl Linker-Based Prodrugs of Atazanavir., 65 (16.0): [PMID:35952307] [10.1021/acs.jmedchem.2c00632] |
Source(1):